Osiris Therapeutics, Inc.
Osiris Therapeutics, Inc., a pioneering leader in regenerative medicine, is headquartered in the United States. Founded in 1992, the company has made significant strides in the development of innovative cellular therapies, particularly in the fields of orthopaedics, wound care, and inflammatory diseases.
Osiris is renowned for its unique core products, including the groundbreaking Grafix® and Ovation® lines, which utilise advanced stem cell technology to promote healing and tissue regeneration. These products stand out in the market due to their ability to enhance recovery while minimising complications.
With a strong market position, Osiris Therapeutics has achieved notable milestones, including regulatory approvals and partnerships that underscore its commitment to advancing healthcare solutions. The company continues to be at the forefront of the regenerative medicine industry, driving research and development to improve patient outcomes.
+16 vs industry average
Osiris Therapeutics, Inc.’s score of 56 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Osiris Therapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Osiris Therapeutics, Inc. yet.
Osiris Therapeutics, Inc.'s reported carbon emissions
Osiris Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Smith & Nephew plc, which may influence its climate commitments and reporting practices.
While Osiris Therapeutics has not established any documented reduction targets or climate pledges, it is important to note that emissions data and sustainability initiatives may be cascaded from its parent company, Smith & Nephew plc. This relationship could potentially align Osiris with broader corporate sustainability goals and practices.
As of now, without specific emissions data or reduction initiatives, Osiris Therapeutics appears to be in the early stages of formalising its climate commitments. The company may benefit from leveraging the sustainability frameworks and targets set by Smith & Nephew to enhance its environmental performance in the future.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Osiris Therapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Osiris Therapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative

Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for Osiris Therapeutics, Inc. yet.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project